Trial · NCT02595996
Propranolol Dose Escalation in Lymphedema in Patients
NCT02595996, Phase 2, Terminated, Columbia University; results first posted 2021-10-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Propranolol Dose Escalation in Lymphedema in Patients. Trials, record NCT02595996. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02595996
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Propranolol Dose Escalation in Lymphedema in Patients
- NCT number
- NCT02595996
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- Columbia University
- Conditions
- Primary Lymphedema
- Interventions
- Propranolol
- First posted
- 2015-11-04
- Last updated
- 2021-10-22
- Results first posted
- 2021-10-22
- Limitations and caveats
- Study terminated due to lack of funding. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1).
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients That Tolerated Propranolol | 8 weeks | To assess whether patients tolerated propranolol |
| Secondary | Number of Patients With Improved Quality of Life Based on Self-reported Questionnaires | 8 weeks | To assess subjective lymphedema symptoms improvements only - whether patients' general quality of life symptoms improved on propranolol treatment by self-reported questionnaires (SF 36) |
| Secondary | Number of Patients With Decreased Fluid Retention by Weight | 8 weeks | To assess whether patients' lymphedema signs are improved on propranolol by weight (BMI kg/m\^2) - objective signs of improvement of their lymphedema |
| Secondary | Number of Patients With Lower Limb Discrepancy | 8 weeks | To assess whether patients' lymphedema signs are improved on propranolol by limb girth discrepancy measurement (%) - objective signs of improvement of their lymphedema |
| Secondary | Number of Patients With Decreased Fluid Retention on MRI | baseline to 8 weeks | To assess whether patients' lymphedema signs are improved on propranolol - the decrease in fluid retention will be calculated by the measurement of fat (a number) divide by the measurement of fluid (a number) to yield a ratio - if a patient has a lower ratio at 8 weeks than at baseline, they will be reported in this category. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patients That Tolerated Propranolol | 8 weeks | Study terminated due to lack of funding. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1). | ||
| SECONDARY | Number of Patients With Improved Quality of Life Based on Self-reported Questionnaires | 8 weeks | Study terminated due to lack of funding. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1). | ||
| SECONDARY | Number of Patients With Decreased Fluid Retention by Weight | 8 weeks | Study terminated due to lack of funding. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1). | ||
| SECONDARY | Number of Patients With Lower Limb Discrepancy | 8 weeks | Study terminated due to lack of funding. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1). | ||
| SECONDARY | Number of Patients With Decreased Fluid Retention on MRI | baseline to 8 weeks | Study terminated due to lack of funding. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1). |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment | 1 | |
| Overall Study | COMPLETED | Treatment | 1 | |
| Overall Study | NOT COMPLETED | Treatment | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment | 0 | 1 |
| Total, other adverse events | Treatment | 0 | 1 |
| Total, serious adverse events | Treatment | 0 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02595996
GET https://conductscience.org/api/trials/v1/NCT02595996/registered